Accelerating research
and development of
new antibiotics and
alternatives
The Netherlands Antibiotic Development Platform
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.
Stay informed on NADP and subscribe to our Update.
NADP Vouchers
An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.
These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.
Latest News
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
EU awards EUR 18 million for research into new antibiotics
An international consortium of research groups aims to develop novel antibiotics against the tuberculosis bacteria and two other deadly bacteria. The European Union has awarded a total of EUR 18 million to the RespiriTB and RespiriNTM projects. Researchers from the Leiden University Medical Centre (LUMC) will be taking part in the study, that is set to last six years.
AGILeBiotics receives NADP lead development voucher for further development of antibiotics
AGILeBiotics has been awarded a Lead Development Voucher by the Netherlands Antibiotic Development Platform (NADP). The total amount of €50.000 will be allocated to the pre-clinical R&D activities. With this financial support the company will test its antibiotic candidates in a clinically relevant animal model of infection. The next goal is the nomination of an antibiotic candidate for pre-clinical development.
NADP Partners
Supported by
NADP Partners
Supported by